# NFAM1

## Overview
NFAM1, or NFAT activating protein with ITAM motif 1, is a gene that encodes a transmembrane receptor protein involved in immune cell signaling. The NFAM1 protein is characterized by its immunoreceptor tyrosine-based activation motif (ITAM), which plays a crucial role in signal transduction processes essential for immune responses. This protein is predominantly expressed in monocytes and neutrophils, with lower levels in B and T cells, and is involved in the activation of nuclear factor of activated T-cells (NFAT), a transcription factor important for regulating immune responses (Ohtsuka2004NFAM1; Juchem2022NFAM1). NFAM1's interactions with kinases such as ZAP-70 and Syk, as well as its involvement in the RANKL signaling pathway, underscore its significance in both immune signaling and osteoclast differentiation (Ohtsuka2004NFAM1; Ethiraj2021Inhibition). The gene's clinical relevance is highlighted by its upregulation in inflammatory diseases and its potential as a therapeutic target (Juchem2022NFAM1; Long2020NFAT).

## Structure
The NFAM1 protein is characterized by several structural features that are crucial for its function in immune signaling. It contains a signal peptide, a transmembrane region, and an extracellular immunoglobulin-like (Ig-like) domain, which are typical of proteins involved in cell signaling and immune response (Ohtsuka2004NFAM1). The cytoplasmic domain of NFAM1 includes an immunoreceptor tyrosine-based activation motif (ITAM), which is essential for signal transduction. In mice, this ITAM contains a YxxLx YxxM sequence, while in humans, it features a YxxLx(7)YxxI sequence, both of which are involved in the recruitment of signaling molecules like ZAP-70/Syk upon activation (Ohtsuka2004NFAM1).

NFAM1 is identified as an N-linked glycoprotein with a molecular weight of approximately 30 kDa, indicating post-translational modifications that may affect its stability and function (Ohtsuka2004NFAM1). The protein's ITAM is phosphorylated upon activation, which is a common post-translational modification that facilitates the recruitment of downstream signaling proteins (Ohtsuka2004NFAM1). The structural analysis of NFAM1 does not provide specific details on its primary, secondary, tertiary, or quaternary structures, nor does it mention splice variant isoforms.

## Function
NFAM1 (NFAT activating protein with ITAM motif 1) is a transmembrane receptor involved in immune cell signaling, particularly in the activation of nuclear factor of activated T-cells (NFAT), a transcription factor crucial for immune response regulation. In healthy human cells, NFAM1 is expressed at high levels in monocytes and neutrophils, with lower expression in B and T cells. It plays a significant role in promoting pro-inflammatory cytokine production, such as TNF-a, IL-13, and IL-2, which are essential for immune responses (Juchem2022NFAM1).

NFAM1 contains an immunoreceptor tyrosine-based activation motif (ITAM), which is critical for its function. Upon activation, NFAM1 can induce ITAM phosphorylation, leading to the recruitment of kinases like ZAP-70 and Syk, and subsequent activation of NFAT. This process is essential for cytokine production and immune cell activation (Ohtsuka2004NFAM1).

In B cells, NFAM1 translocates to lipid rafts upon antigen receptor stimulation, enhancing B cell receptor signaling. This suggests a role in modulating B cell development and signaling pathways, although its impact on B cell function in healthy human cells remains less clear (Ohtsuka2004NFAM1).

## Clinical Significance
The NFAM1 gene is clinically significant due to its involvement in various diseases through alterations in its expression and interactions. NFAM1 is upregulated in inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis, where it promotes the production of pro-inflammatory cytokines, contributing to inflammation (Juchem2022NFAM1). In coronary artery disease (CAD), NFAM1 is significantly upregulated on monocytes, enhancing monocyte chemotaxis and potentially contributing to atherosclerosis progression (Long2020NFAT). Its expression correlates with chemokine receptors CCR2 and CCR5, suggesting a role in monocyte recruitment and CAD pathogenesis (Long2020NFAT).

In bone-related diseases, NFAM1 is implicated in osteoclast differentiation and bone resorption, particularly in Paget's disease of bone. It modulates signaling pathways crucial for osteoclast formation, and its inhibition reduces bone resorption activity (Ethiraj2021Inhibition; Sambandam2017NFAM1). These findings highlight NFAM1 as a potential therapeutic target for autoimmune and inflammatory diseases, as its modulation could reduce inflammation and disease progression without broad immunosuppression (Juchem2022NFAM1).

## Interactions
NFAM1 (NFAT activating protein with ITAM motif 1) is involved in several protein interactions that are crucial for its role in immune signaling and osteoclast differentiation. NFAM1 contains an immunoreceptor tyrosine-based activation motif (ITAM), which facilitates the recruitment of kinases such as ZAP-70 and Syk upon activation. This interaction is essential for the phosphorylation of NFAM1 and subsequent signal transduction processes (Ohtsuka2004NFAM1).

In the context of osteoclast differentiation, NFAM1 interacts with components of the RANKL signaling pathway. It modulates the SAPK/JNK signaling pathway, which is critical for osteoclast formation. NFAM1 knockdown results in the suppression of c-Fos and p-c-Jun expression, key components of the AP-1 transcription factor complex, indicating its role in regulating these interactions (Ethiraj2021Inhibition).

NFAM1 also influences the calcineurin/NFAT signaling pathway, particularly in the context of Paget's disease of bone. It is involved in the phosphorylation of ITAM, recruitment of ZAP-70/Syk, and activation of calcineurin and NFATc1, which are critical for osteoclast differentiation (Sambandam2017NFAM1). These interactions highlight NFAM1's role in both immune and bone resorption processes.


## References


[1. (Ohtsuka2004NFAM1) Makoto Ohtsuka, Hisashi Arase, Arata Takeuchi, Sho Yamasaki, Ritsuko Shiina, Tadahiro Suenaga, Daiju Sakurai, Tadashi Yokosuka, Noriko Arase, Makio Iwashima, Toshio Kitamura, Hideshige Moriya, and Takashi Saito. Nfam1, an immunoreceptor tyrosine-based activation motif-bearing molecule that regulates b cell development and signaling. Proceedings of the National Academy of Sciences, 101(21):8126–8131, May 2004. URL: http://dx.doi.org/10.1073/pnas.0401119101, doi:10.1073/pnas.0401119101. This article has 91 citations.](https://doi.org/10.1073/pnas.0401119101)

[2. (Ethiraj2021Inhibition) Purushoth Ethiraj, Ishraq A. Haque, Anna K. Alford, Wenyu Gou, Toolika Singh, Yuvaraj Sambandam, Jessica D. Hathaway‐Schrader, and Sakamuri V. Reddy. Inhibition of nfam1 suppresses phospho‐sapk/jnk signaling during osteoclast differentiation and bone resorption. Journal of Cellular Biochemistry, 122(10):1534–1543, July 2021. URL: http://dx.doi.org/10.1002/jcb.30076, doi:10.1002/jcb.30076. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcb.30076)

[3. (Sambandam2017NFAM1) Yuvaraj Sambandam, Kumaran Sundaram, Takamitsu Saigusa, Sundaravadivel Balasubramanian, and Sakamuri V. Reddy. Nfam1 signaling enhances osteoclast formation and bone resorption activity in paget’s disease of bone. Bone, 101:236–244, August 2017. URL: http://dx.doi.org/10.1016/j.bone.2017.05.013, doi:10.1016/j.bone.2017.05.013. This article has 10 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bone.2017.05.013)

[4. (Long2020NFAT) Jie Long, Jiemei Chen, Qingchun Wang, Feng Gao, Ming Lian, Peng Zhang, Yuejin Yang, and Haibo Zhu. Nfat activating protein with itam motif 1 (nfam1) is upregulated on circulating monocytes in coronary artery disease and potentially correlated with monocyte chemotaxis. Atherosclerosis, 307:39–51, August 2020. URL: http://dx.doi.org/10.1016/j.atherosclerosis.2020.06.001, doi:10.1016/j.atherosclerosis.2020.06.001. This article has 3 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.atherosclerosis.2020.06.001)

[5. (Juchem2022NFAM1) Kathryn W. Juchem, Anshu P. Gounder, Jian Ping Gao, Elise Seccareccia, Narayana Yeddula, Nicholas J. Huffmaster, Alexandra Côté-Martin, Steven E. Fogal, Donald Souza, Sarah Sirui Wang, Elizabeth R. A. Glynn, Ivy Yung, Julie Ritchie, Li Li, Jie Zheng, M. Lamine Mbow, Jun Li, and Sumit K. Chanda. Nfam1 promotes pro-inflammatory cytokine production in mouse and human monocytes. Frontiers in Immunology, January 2022. URL: http://dx.doi.org/10.3389/fimmu.2021.773445, doi:10.3389/fimmu.2021.773445. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2021.773445)